Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study SARS-CoV-2-CZ-PREVAL-II - Arm of the Olomouc Region Study to Quantify the Presence of Antibodies and Cellular Immunity Against SARS-CoV-2 in the Population of Persons Participating in the SARS-CoV-2-CZ-PREVAL Study in 2020

NCT07387211 is registered in ClinicalTrials.gov with The Institute of Molecular and Translational Medicine, Czech Republic as lead sponsor.

NCT NCT07387211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07387211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study SARS-CoV-2-CZ-PREVAL-II - Arm of the Olomouc Region Study to Quantify the Presence of Antibodies and Cellular Immunity Against SARS-CoV-2 in the Population of Persons Participating in the SARS-CoV-2-CZ-PREVAL Study in 2020
Lead sponsor
The Institute of Molecular and Translational Medicine, Czech Republic
Phase
Not applicable
Overall status
Completed
Start date
January 18, 2022
Completion date
October 13, 2022
Enrollment
2,484 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2, sars-cov-2 (covid-19) infection